Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that spironolactone at 200 mg/day significantly improved facial hair growth in women with hirsutism and showed a sustained reduction in ovarian androgens over one year.

This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.

This study found that spironolactone reduced serum androstenedione and anagen hair shaft diameter in hirsute patients but did not significantly alter unbound testosterone levels, suggesting its effects are primarily peripheral.

This study found that the opioid system, particularly via the delta opioid receptor, broadly regulates cutaneous mechanosensation, including touch, and suggests targeting this receptor could alleviate injury-induced mechanical hypersensitivity.

This study found that spironolactone significantly reduced hair growth in hirsute women, with noticeable effects in 3-5 months, and decreased serum testosterone levels in all participants.

This systematic review concluded that the support for using spironolactone at commonly prescribed doses is based on evidence of limited quality.

This review found some evidence suggesting that spironolactone can effectively reduce hirsutism in women but did not support its use for treating acne vulgaris.

This article discusses oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia and reports no new clinical results.

This study found that blocking GABA(A) receptors in cat dorsal horn neurons increased evoked activity and background discharge, highlighting differences in inhibitory control systems compared to glycine receptors.

This study found that spironolactone, flutamide, and finasteride are similarly effective in reducing hair diameter and Ferriman-Gallwey scores in women with hirsutism over a 6-month treatment period.

This study suggests that spironolactone-loaded nanostructured lipid carriers could enhance follicular delivery and offer a more localized treatment for androgenic alopecia, potentially reducing systemic side effects.

This study observed that high-dose spironolactone frequently caused metrorrhagia in women with idiopathic hirsutism, leading the authors to suggest lower starting doses or additional hormonal therapy.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

This study found that in hirsute women, daily treatment with 200 mg spironolactone significantly reduced hair growth rates and hair shaft diameters on various body areas over 12 months.

This study found that spironolactone was significantly more effective than finasteride in reducing hirsutism scores over 9 months, despite more side effects occurring in the spironolactone group.

This study found that combining low-dose spironolactone with metformin provided greater clinical benefits and improved treatment compliance in women with PCOS compared to either drug alone.

This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.

This study found that while cyproterone acetate, finasteride, and spironolactone had similar short-term effects in treating idiopathic hirsutism, spironolactone provided more lasting benefits one year after treatment.

This study reports that oral spironolactone may be a useful and low-cost first-line treatment for hidradenitis suppurativa in women, with relatively few side effects.

This paper discusses spironolactone as a potential off-label treatment for female pattern hair loss, noting its ability to halt hair loss progression and induce partial regrowth in a significant number of women but reports no new clinical results.

This study observed that finasteride and spironolactone both led to a similar significant, but limited, improvement in hirsutism despite their differing effects on androgen levels.

This study found that spironolactone directly inhibits 5 alpha-reductase activity in hirsute women, resulting in decreased conversion of testosterone to dihydrotestosterone, which may contribute to its therapeutic effects.

This study observed that in vitro exposure to dihydrotestosterone worsened COVID-19 spike protein-induced endothelial injury, while spironolactone showed potential in reducing this effect, suggesting a rationale for further evaluation in treating COVID-19.

This study found that spironolactone treatment can normalize endothelial function and improve cholesterol levels in non-obese patients with polycystic ovary syndrome.

This study observed that treatment with spironolactone significantly improved pain, inflammatory lesion count, and HS-PGA scores among female patients with hidradenitis suppurativa, suggesting its potential as an effective treatment option, even at lower doses, despite no change in Hurley stage or fistula count.

This study found that the combination of spironolactone and finasteride significantly improved hirsutism scores more than spironolactone alone in women, with similar side-effect profiles between treatments.

This study suggests that combination drug therapy with spironolactone and either oral contraceptives or dexamethasone effectively manages unresponsive hirsutism, with eight of nine patients achieving satisfactory clinical responses.

Kennedy's disease leads to muscle weakness without a cure, but exercise and managing symptoms may help patients live a normal lifespan.

This study found that in the dorsal horn's lamina III, most afferent boutons form synapses with presynaptic boutons immunoreactive for GABA and/or glycine, influencing sensory pathways.